Respiratory Medicine
Volume 103, Issue 6 , Pages 919-926 , June 2009

Clinical, functional and biochemical changes during recovery from COPD exacerbations

  • Angela Koutsokera

      Affiliations

    • Department of Respiratory Medicine, University Hospital of Larissa, University of Thessaly Medical School, Larissa 41110, Greece
    • ,
  • Theodoros S. Kiropoulos

      Affiliations

    • Department of Respiratory Medicine, University Hospital of Larissa, University of Thessaly Medical School, Larissa 41110, Greece
    • ,
  • Dimitrios J. Nikoulis

      Affiliations

    • Department of Immunology and Histocompatibility, University Hospital of Larissa, University of Thessaly Medical School, Larissa 41110, Greece
    • ,
  • Zoe D. Daniil

      Affiliations

    • Department of Respiratory Medicine, University Hospital of Larissa, University of Thessaly Medical School, Larissa 41110, Greece
    • ,
  • Vassiliki Tsolaki

      Affiliations

    • Department of Respiratory Medicine, University Hospital of Larissa, University of Thessaly Medical School, Larissa 41110, Greece
    • ,
  • Kalliopi Tanou

      Affiliations

    • Department of Respiratory Medicine, University Hospital of Larissa, University of Thessaly Medical School, Larissa 41110, Greece
    • ,
  • Andriana I. Papaioannou

      Affiliations

    • Department of Respiratory Medicine, University Hospital of Larissa, University of Thessaly Medical School, Larissa 41110, Greece
    • ,
  • Anastasios Germenis

      Affiliations

    • Department of Immunology and Histocompatibility, University Hospital of Larissa, University of Thessaly Medical School, Larissa 41110, Greece
    • ,
  • Konstantinos I. Gourgoulianis

      Affiliations

    • Department of Respiratory Medicine, University Hospital of Larissa, University of Thessaly Medical School, Larissa 41110, Greece
    • ,
  • Konstantinos Kostikas

      Affiliations

    • Department of Respiratory Medicine, University Hospital of Larissa, University of Thessaly Medical School, Larissa 41110, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30 6944780616; fax: +30 2410670240.

Received 13 April 2008 ,Accepted 4 December 2008.

References 

  1. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29:1224–1238
  2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946
  3. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852
  4. Parker CM, Voduc N, Aaron SD, et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J. 2005;26:420–428
  5. Pinto-Plata VM, Livnat G, Girish M, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest. 2007;131:37–43
  6. Gompertz S, O'Brien C, Bayley DL, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17:1112–1119
  7. Groenewegen KH, Dentener MA, Wouters EF. Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD. Respir Med. 2007;101:2409–2415
  8. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007;29:527–534
  9. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204
  10. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s–53s
  11. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555
  12. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383
  13. Marti S, Munoz X, Rios J, et al. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J. 2006;27:689–696
  14. Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999;15:116–122
  15. Daniil ZD, Papageorgiou E, Koutsokera A, et al. Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2008;21:26–31
  16. Harrell FE, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988;80:1198–1202
  17. von Leupoldt A, Dahme B. Psychological aspects in the perception of dyspnea in obstructive pulmonary diseases. Respir Med. 2007;101:411–422
  18. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1638–1645
  19. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867–874
  20. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84:210–215
  21. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:349–355
  22. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–120
  23. Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 2005;60:293–300
  24. Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid A is a biomarker of acute exacerbations of COPD. Am J Respir Crit Care Med. 2008;177:269–278
  25. Marhaug G, Permin H, Husby G. Amyloid-related serum protein (SAA) as an indicator of lung infection in cystic fibrosis. Acta Paediatr Scand. 1983;72:861–866
  26. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477–1482
  27. Meier CR, Jick SS, Derby LE, et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet. 1998;351:1467–1471
  28. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58:589–593
  29. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1613
  30. Franciosi LG, Page CP, Celli BR, et al. Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res. 2006;7:74

PII: S0954-6111(08)00450-2

doi: 10.1016/j.rmed.2008.12.006

Respiratory Medicine
Volume 103, Issue 6 , Pages 919-926 , June 2009

Article Tools

* Image Usage & Resolution